Capital Fund Management S.A. Invests $2.12 Million in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Capital Fund Management S.A. has acquired a new stake in Agios Pharmaceuticals, purchasing 72,302 shares valued at approximately $2.12 million, representing around 0.12% of the company.
• Agios Pharmaceuticals' stock is currently priced at $38.80, with a market capitalization of $2.25 billion and a 52-week range between $23.42 and $62.58.
• Despite achieving a revenue of $12.50 million, Agios reported earnings per share of ($1.93), missing consensus estimates and signaling a challenging quarter for the company.

Capital Fund Management S.A. bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 72,302 shares of the biopharmaceutical company's stock, valued at approximately $2,118,000. Capital Fund Management S.A. owned about 0.12% of Agios Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $39,000. CWM LLC increased its holdings in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 996 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 499 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Agios Pharmaceuticals by 9,296.6% in the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock valued at $240,000 after purchasing an additional 8,088 shares during the last quarter. Finally, Commerce Bank purchased a new position in Agios Pharmaceuticals in the first quarter worth approximately $240,000.

Agios Pharmaceuticals Stock Down 2.8%

Shares of AGIO traded down $1.09 on Thursday, reaching $38.18. The stock had a trading volume of 433,157 shares, compared to its average volume of 704,952. The firm has a 50-day moving average of $37.00 and a 200 day moving average of $32.98. The firm has a market capitalization of $2.22 billion, a PE ratio of 3.47 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 18,700 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the transaction, the chief executive officer owned 105,401 shares of the company's stock, valued at $3,535,149.54. This represents a 15.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider James William Burns sold 2,799 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $93,878.46. Following the transaction, the insider directly owned 28,650 shares in the company, valued at approximately $960,921. This represents a 8.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,448 shares of company stock worth $2,026,141. Company insiders own 4.30% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on AGIO. Bank of America lowered their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Finally, Scotiabank decreased their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.